Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809848 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT00809848: Completed Phase 1 study, sponsored by Allergan.
NCT00809848 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 172 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00809848, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.
Primary Outcome
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG AGN-210669 ophthalmic solution, 0.075%
- DRUG AGN-210669 ophthalmic solution, 0.05%
- DRUG AGN-210669 ophthalmic solution, 0.025%
- DRUG AGN-210669 vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
What the finished NCT00809848 record still lists
NCT00809848 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher).
The record links to 0 conditions, and to 5 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT00809848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00809848 about?
NCT00809848 is a clinical study titled "Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma". The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.
What is the current status of trial NCT00809848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2009-02. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00809848?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), AGN-210669 ophthalmic solution, 0.075% (DRUG), AGN-210669 ophthalmic solution, 0.05% (DRUG), AGN-210669 ophthalmic solution, 0.025% (DRUG), AGN-210669 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00809848?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00809848's enrollment target sits among peer trials
172 324th of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia